Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture).
The updated Clinician's Guide provides recommendations on prevention, risk assessment, diagnosis, and treatment of osteoporosis in older adults. It highlights the latest research and improvements in diagnostic technologies and treatments, and aims to improve patient care and reduce fracture risk.
In the new guideline, ACP recommends bisphosphonates as initial pharmacologic treatment to reduce the risk of fractures in males and postmenopausal females diagnosed with primary osteoporosis.
The Food and Drug Administration (FDA) recently approved romosozumab (Evenity), a new drug for osteoporosis. Unlike osteoporosis medicines called bisphosphonates, romosozumab doesn’t just stop bone loss; it also helps build new bone.
Jubbonti and Wyost are interchangeable biosimilars to Prolia and Xgeva, respectively, for treating osteoporosis, preventing bone events in cancer, and treating giant cell tumor of bone. They...
This research opens up new possibilities for developing innovative treatments for osteoporosis. The next steps involve testing iSN40's effectiveness in animal models and, eventually, in...
Learn about bisphosphonates, a common type of osteoporosis medicine that reduces bone breakdown and strengthens bone. Find out how they work, what side effects they may cause, and when to consider a drug holiday or other treatments.
The Clinician's Guide offers concise recommendations regarding prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men aged 50 years and older. It includes indications for bone densitometry as well as fracture risk thresholds for pharmacologic intervention.
Learn about the new recommendations from the American College of Obstetricians and Gynecologists (ACOG) for managing osteoporosis, including new medications and targeted treatments. Find out how...
Final NICE guidance said that the usual treatments for osteoporosis after menopause include the anabolic (or bone-forming) medicines romosozumab or teriparatide, and antiresorptive medicines such as bisphosphonates, including alendronic acid, which slow the rate of bone breakdown.